Pre_GI: SWBIT SVG BLASTN

Query: NC_018145:104303 Zymomonas mobilis subsp. mobilis ATCC 29191 chromosome, complete

Lineage: Zymomonas mobilis; Zymomonas; Sphingomonadaceae; Sphingomonadales; Proteobacteria; Bacteria

General Information: Isolation: Fermenting Elaeis palm sap; Temp: Mesophile. The natural habitat of this organism includes sugar-rich plant saps where the bacterium ferments sugar to ethanol. The high conversion of sugars to ethanol makes this organism useful in industrial production systems, particularly in production of bioethanol for fuel. A recombinant strain of this bacterium is utilized for the conversion of sugars, particularly xylose, which is not utilized by another common sugar-fermenting organism such as yeast, to ethanol. Since xylose is a common breakdown product of cellulose or a waste component of the agricultural industry, it is an attractive source for ethanol production. Zymomonas mobilis was chosen for this process as it is ethanol-tolerant (up to 120 grams of ethanol per litre) and productive (5-10% more ethanol than Saccharomyces). This bacterium ferments using the Enter-Doudoroff pathway, with the result that less carbon is used in cellular biomass production and more ends up as ethanol, another factor that favors this organism for ethanol production.

- Sequence; - BLASTN hit (Low score = Light, High score = Dark)
- hypothetical protein; - cds: hover for description

BLASTN Alignment.txt

Subject: NC_007164:453743 Corynebacterium jeikeium K411, complete genome

Lineage: Corynebacterium jeikeium; Corynebacterium; Corynebacteriaceae; Actinomycetales; Actinobacteria; Bacteria

General Information: This strain was isolated from the axilla of a bone marrow transplant patient. A serious nocosomial pathogen. This bacterium is a lipophilic and multidrug resistant member of the human skin flora. This species has been associated with bacterial endocarditis following cardiac surgery. Other nocosomial infections involving this organism are associated with immunocompromised patients with malignancies, in-place medical devices, breaks in the skin barrier, and therapy with broad-spectrum antibiotics.